---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-262976"
form_type: "8-K/A"
ticker: "XAGE"
cik: "0001842939"
company_name: "Longevity Health Holdings, Inc."
filed_at: "2023-10-25T23:59:59+00:00"
generated_at: "2026-06-09T11:37:23.816419+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Carmell Corp files Axolotl Biologix H1 2023 financials: rev $21.9M, NI $1.8M

## Summary
- Axolotl H1 2023 revenue $21.9M (up 56% YoY from $14.0M) and net income $1.8M (up 57% from $1.2M).
- Single customer (Customer A) and single product (Dualgraft) represent 100% of revenue.
- Cash and equivalents $698k; accounts receivable $17.2M; inventory $2.6M.
- Related-party loans from Burns Ventures $5.6M noncurrent; inventory purchases from Pinnacle $2.5M in H1 2023.
- Operating cash flow negative $701k; cash decreased from $1.4M to $698k in H1 2023.

## SEC filing metadata
- accession: 0001193125-23-262976
- form_type: 8-K/A
- ticker: XAGE
- cik: 0001842939
- company_name: Longevity Health Holdings, Inc.
- filed_at: 2023-10-25T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1842939/000119312523262976/0001193125-23-262976-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1842939/000119312523262976/d568161d8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-262976
- JSON: https://secwatch.observer/filing/0001193125-23-262976.json
- Plain text: https://secwatch.observer/filing/0001193125-23-262976.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.